March 6, 2026 — Vancouver, British Columbia, Canada
InMed Pharmaceuticals Inc. has announced a significant strategic update regarding the operations of its wholly owned subsidiary BayMedica LLC, confirming plans to wind down BayMedica’s commercial operations and redirect corporate resources toward advancing its pharmaceutical drug development pipeline. The decision comes amid regulatory uncertainty tied to proposed U.S. federal legislation, which could impact the commercialization of certain rare cannabinoid ingredients currently produced by BayMedica. The strategic shift underscores InMed’s intention to focus on high-value pharmaceutical research programs targeting serious diseases such as Alzheimer’s disease and ocular disorders, positioning the company to prioritize long-term innovation and clinical development opportunities.
Strategic Exit from BayMedica Commercial Operations
The company revealed that its board of directors approved the decision to gradually wind down BayMedica’s commercial operations segment, a move designed to mitigate potential financial and regulatory risks associated with evolving U.S. legislation. Specifically, the proposed federal legislation known as H.R. 5371 – the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 could significantly restrict certain commercial activities related to rare non-intoxicating cannabinoids, which currently form part of BayMedica’s product portfolio.
If enacted without amendments, the legislation could prohibit certain aspects of BayMedica’s operations and inventory beginning November 12, 2026, creating uncertainty around the long-term viability of the subsidiary’s commercial activities. After conducting a detailed evaluation of available options and the broader regulatory landscape, company leadership determined that exiting BayMedica’s commercial segment would best position InMed to protect shareholder value and focus on its core pharmaceutical development strategy.
BayMedica is expected to complete the operational wind-down prior to the end of InMed’s fiscal year on June 30, 2026. During the transition period, the subsidiary will continue limited commercial activities including product sales, marketing operations, selective manufacturing, and logistics support in order to maintain business continuity and minimize disruption for customers and partners.
Advertisement
Accelerating Focus on Pharmaceutical Drug Development
Following the planned wind-down, InMed will focus its resources on advancing its proprietary pipeline of small-molecule drug candidates targeting the CB1 and CB2 receptor pathways, which are believed to play an important role in neurological, inflammatory, and ocular diseases. The company is currently developing several investigational therapies designed to address high-unmet medical needs across multiple therapeutic areas.
Among the most advanced programs is INM-901, a drug candidate being explored for the treatment of Alzheimer’s disease, a neurodegenerative disorder affecting millions of patients worldwide. The therapy is being developed as a disease-modifying treatment designed to address underlying disease mechanisms rather than simply managing symptoms. Another promising candidate, INM-089, is being investigated for the treatment of dry age-related macular degeneration (AMD), a leading cause of vision loss among older adults.
Both programs are progressing toward Investigational New Drug (IND) applications and early-stage human clinical trials, which represent critical milestones in the development of innovative pharmaceutical therapies. By reallocating resources previously dedicated to BayMedica’s commercial operations, the company intends to accelerate clinical development timelines and strengthen its long-term pharmaceutical research capabilities.
Company leadership emphasized that the strategic shift reflects a commitment to prioritizing innovative drug discovery and clinical development initiatives with the greatest potential to generate long-term value for patients and investors.
Managing Financial and Operational Transition
InMed expects the transition to be executed in a structured and responsible manner designed to minimize disruption to employees, customers, and suppliers. BayMedica’s management team is currently developing a comprehensive transition plan that will outline operational changes and communicate next steps to stakeholders affected by the restructuring.
The company anticipates that the wind-down process will result in approximately $550,000 in employee-related costs, including severance payments, along with an additional $120,000 in operational expenses associated with completing the transition by the end of the fiscal year. However, these costs are expected to be partially offset by continued sales of BayMedica’s existing products during the wind-down period.
InMed has also disclosed preliminary financial information related to the transition through a Form 8-K filing with the U.S. Securities and Exchange Commission, providing transparency regarding the financial implications of the restructuring. The company plans to share additional updates on its pharmaceutical pipeline development strategy and financial outlook in future investor communications and regulatory filings.
With the planned restructuring, InMed aims to streamline its operational focus and strengthen its position as a pharmaceutical innovation company dedicated to developing disease-modifying therapies targeting cannabinoid receptor pathways. As global pharmaceutical research continues to explore new therapeutic approaches for neurological and ocular diseases, the company’s refined strategic direction is expected to support the advancement of next-generation drug candidates designed to address significant unmet medical needs.
z
Source: InMed Pharmaceuticals press release
